Pharma VC Funds

Mirae Asset Venture Investments is the venture capital arm of Mirae Asset Financial Group, a global financial services giant headquartered in South Korea. The venture fund focuses on early to growth-stage investments, particularly in the technology, life sciences, fintech, and consumer sectors. Their portfolio features prominent companies like Unacademy, Ola, Zomato, and Bigbasket, reflecting their strong interest in emerging markets and digital platforms. Geographically, the fund has a significant presence across Asia, particularly in India and Southeast Asia, as well as North America. Mirae Asset employs a long-term, research-driven investment strategy, often co-investing with other prominent VC firms like SIG Venture Capital and Peak XV Partners. They have been especially active in 2024, making several key investments across various sectors, including fintech startup Jupiter and online grocery platform HappyFresh. With a focus on strategic growth, they seek companies that can redefine industries or introduce innovative solutions, and provide not just capital but also robust portfolio management. Their team, led by key executives like Ashish Dave in India, supports portfolio companies with deep market insights and hands-on guidance​.

Miroma Ventures is the investment arm of The Miroma Group, focusing primarily on venture and growth-stage investments in consumer brands and media platforms. Based in London, the firm leverages the extensive marketing expertise and global network of The Miroma Group to accelerate the growth of its portfolio companies. This unique approach allows Miroma Ventures to offer a mix of capital investment and tailored marketing services, making them a strategic partner for companies looking to expand their reach and scale rapidly. Miroma Ventures typically invests in the Seed, Series A, and Series B stages, with investment sizes ranging from $250,000 to $5 million. The firm is known for its interest in sectors like food and beverage, beauty and personal care, e-commerce, and digital media. They also offer flexible financing solutions, such as media services in exchange for equity, combining both financial and marketing support. The company has backed over 50 brands globally, including well-known names like ClassPass and Pinterest, reflecting its strong track record in the consumer and media industries. Miroma Ventures is particularly interested in partnering with businesses that show strong growth potential and can leverage its marketing expertise to build long-term value. With its focus on purpose-driven investments and consumer engagement, Miroma Ventures continues to support innovative brands that connect with modern audiences while fostering substantial growth.

Mission Bay Capital is a venture capital firm based in San Francisco, focused on early-stage investments in the biosciences. Established in 2009, the firm aims to support innovative entrepreneurs addressing critical medical and environmental challenges. Their portfolio includes companies like Caribou Biosciences, Alector, Zymergen, and Mammoth Biosciences, which utilize cutting-edge technologies such as CRISPR for molecular diagnostics​​. The firm has recently raised its third fund, totaling $60 million, which will continue to invest broadly in biotechnology innovations. Mission Bay Capital operates MBC BioLabs, a life-science incubator that has helped launch 138 companies, raising over $3.5 billion in total. This incubator provides state-of-the-art equipment and services to early-stage biotech companies, enabling them to advance their research and development efficiently​. Mission Bay Capital is led by Douglas Crawford, Ph.D., along with a team of experienced professionals like Robert Blazej, Ph.D. They emphasize disciplined investing and a management culture rooted in respect and inclusion, aiming to deliver superior returns and strategic opportunities to their limited partners​.

Mission BioCapital, founded in 2009, is a venture capital firm that focuses on early-stage investments in life sciences companies. With offices in Cambridge, Massachusetts, and San Francisco, California, the firm supports startups from the idea phase through to key development milestones. Mission BioCapital emphasizes collaboration and innovation, providing capital and strategic support to help scientific solutions reach the clinic faster and more efficiently. The firm recently announced raising $275 million for its fifth fund, Mission BioCapital V, which is aimed at funding transformative startups in therapeutics, diagnostics, medical devices, laboratory tools, and drug delivery. This fund also emphasizes company creation, working with academic researchers and entrepreneurs to launch startups based on novel technologies. Notable portfolio companies include Caribou Biosciences, Effector Therapeutics, and Alector, with several successful exits and IPOs. Mission BioCapital has also co-founded companies like ARase Therapeutics, Arclight Therapeutics LLC, Jupiter Bioventures, and Telo Therapeutics, demonstrating its deep involvement in nurturing groundbreaking life science ventures. The team at Mission BioCapital includes experienced professionals like Dr. Michael D. Taylor, who has a significant background in drug development at Pfizer and startups like Deciphera Pharmaceuticals. Co-Managing Partner Steve Tregay also brings extensive experience from his tenure at FORMA Therapeutics and the Novartis Venture Fund.

MissionPoint Partners, established in 2006, is a leading impact investment firm focused on addressing large-scale environmental and social challenges. By mobilizing high-impact capital, the firm collaborates with families, foundations, and institutions to drive both financial returns and measurable social change. With expertise in climate tech, sustainability, and renewable energy, MissionPoint Partners has built a reputation for backing companies that generate meaningful environmental impact while also being commercially viable. MissionPoint's portfolio features prominent companies like AeroFarms, a pioneer in vertical farming that focuses on sustainable food production, and Opti, which develops data-driven environmental solutions to improve water management. The firm also played a pivotal role in acquiring ImpactUs, a platform designed to facilitate private impact investments by connecting capital with impactful projects​. With an emphasis on renewable energy, food and agriculture tech, and environmental technologies, MissionPoint works to ensure its investments lead to significant climate and social benefits. The firm is particularly known for its involvement in the growth of Hannon Armstrong, a leader in sustainable infrastructure, which went public on the New York Stock Exchange in 2013​. MissionPoint has co-invested with major players such as Zouk Capital and VantagePoint Capital, aligning its capital with some of the most forward-thinking funds in the climate space​. Through its innovative approach and strategic partnerships, MissionPoint Partners continues to empower businesses that tackle pressing global issues while achieving sustainable growth.

Mistletoe, a venture capital firm based in Kanazawa, Japan, was founded by Taizo Son and Atsushi Taira in 2013. The fund focuses on early-stage investments in tech-driven startups with a strong emphasis on sustainability and social impact. Notable investments include Zipline, Playco, and Sea, reflecting their commitment to innovative and impactful ventures. Mistletoe's industry focus spans across biotechnology, clean energy, health tech, and entertainment, showing a diverse portfolio aimed at transformative technologies. Geographically, their investments are global, covering North America, Asia, and Europe, with recent activities in countries like Japan, the U.S., and Finland. Their strategy revolves around partnering with visionary founders who tackle global challenges. Mistletoe typically invests in seed to series A stages, often leading rounds with an average check size of around $2 million. They have a collaborative approach, frequently co-investing with firms like Sequoia Capital and Plug and Play Tech Center. Active in fostering an ecosystem of like-minded investors and entrepreneurs, Mistletoe values innovation and societal contributions highly. The team, including key members like Michael Kim and Satoshi Fujimura, is primarily based in Japan with a significant presence in Singapore. Startups looking to engage with Mistletoe should emphasize their mission-driven goals and innovative solutions. Approaching them through warm introductions and clear, impactful pitches increases the chances of successful engagement​.

Mithril Capital, founded in 2012 by Ajay Royan and Peter Thiel, is a venture capital firm based in Austin, Texas. The firm focuses on long-term investments across various sectors and geographies, partnering with teams that leverage technology to create lasting and valuable businesses. Mithril's investment philosophy emphasizes broadminded curiosity, capital discipline, and constructive skepticism, seeking to support industries that are ripe for technological disruption. Mithril's portfolio includes notable companies such as Helion Energy, which is pioneering fusion energy; Neocis, which is advancing robotics in dental surgery; and Glance, a rapidly growing consumer internet platform. Other significant investments include Nuvia (acquired by Qualcomm), Auris Health (acquired by Johnson & Johnson), and BlackSky, a leader in real-time geospatial intelligence. The firm prides itself on helping companies navigate critical growth inflection points, supporting them with strategic insights and substantial capital investments. This approach has enabled Mithril's portfolio companies to achieve remarkable advancements in their respective fields, from reshaping robotic surgery to revolutionizing decentralized finance and enhancing grid resilience with AI-driven energy storage solutions.

Mitsui & Co., a leading global trading and investment company, has a diverse portfolio across multiple industries. Founded in 1876 and headquartered in Tokyo, Mitsui has expanded its operations globally, focusing on sectors such as energy, healthcare, technology, and consumer goods. Notable investments by Mitsui & Co. include Lhyfe, a French company specializing in renewable green hydrogen production, aligning with Mitsui’s commitment to sustainable energy solutions. QurAlis, a biotechnology company, is developing precision medicines for ALS and other neurodegenerative diseases. Leash Biosciences is an AI-driven biotech firm revolutionizing medicinal chemistry. Kaltura, a leading video technology provider, went public through an IPO. Virident, a high-performance storage class memory solutions company, was acquired. Boston Biomedical focuses on novel cancer treatments. Proterra, a manufacturer of zero-emission vehicles, merged through a SPAC. Mitsui & Co. leverages its global network and industry expertise to support innovative companies and foster growth in various sectors.

MMC Ventures is a London-based venture capital firm that has been supporting early-stage tech entrepreneurs for over 20 years. Focused on transformative technology, MMC specializes in sectors such as artificial intelligence (AI), data-driven health, fintech, and enterprise software. The firm has built a reputation for deep industry expertise, particularly in AI and data science, where it is one of Europe's most active investors. Notable investments include Synthesia, Signal AI, and Current Health, the latter of which was acquired by Best Buy. MMC’s investment strategy is research-led, with a dedicated team of specialists who help identify and develop cutting-edge technologies. They typically invest in Seed and Series A rounds, but a significant portion of their funds is reserved for follow-on rounds, ensuring long-term support for portfolio companies. MMC also places a strong emphasis on partnering closely with founders, providing more than just capital; they offer resources like MMC Connect, a platform that facilitates introductions, coaching, and talent acquisition. In recent years, MMC has expanded its portfolio across Europe, backing companies in markets from the UK to Eastern Europe. The firm is committed to building businesses with the potential to drive technological advancements and create a positive impact on society, as evidenced by its status as one of the first B Corporations in venture capital.

Mobile Internet Capital (MIC), established in 1999, is a venture capital firm based in Japan. The firm focuses on investing in innovative technology companies with a strong emphasis on internet and mobile-related sectors. MIC has a successful track record with 22 IPOs and numerous exits. Their portfolio includes companies like Gree, a social networking service provider, and Mercari, a popular marketplace app. MIC invests in early to growth-stage companies, supporting them through multiple rounds to help them achieve significant milestones and market expansion. MIC is known for its strategic approach, leveraging its deep industry knowledge and network to provide not only capital but also valuable guidance and connections to its portfolio companies. They aim to foster long-term growth and innovation in the tech industry.

Moment Ventures is an early-stage venture capital firm headquartered in Palo Alto, focusing on transformative technology solutions that reimagine the future of industries. The firm invests in startups at the pre-seed and seed stages, partnering with founders who are developing innovative business models and solutions to improve how industries operate. Moment Ventures is particularly focused on sectors that are evolving due to technology, such as logistics, education, e-commerce, software, and the future of work. Moment Ventures’ investment strategy revolves around leading financings and often taking board seats or observer roles to support their portfolio companies. Their investments are thematically centered on "Business at the Speed of Software," "Future of Workers," and "Masters of the Machines." This focus allows them to back founders who are creating technology that enhances productivity and efficiency across industries. Founded by Ammar Hanafi and Clint Chao in 2015, the firm leverages deep domain expertise from years of venture capital and operating experience to guide their portfolio companies through early-stage challenges. Notable exits from their portfolio include companies like Payable (acquired by Stripe) and Twin Prime (acquired by Salesforce), highlighting their ability to nurture successful startups. Moment Ventures remains dedicated to its mission of supporting early-stage entrepreneurs who are fundamentally changing industries and empowering workers to succeed in the evolving economy. They believe in building strong partnerships with founders, offering not just capital but strategic insight to ensure long-term success.

Montage Ventures, headquartered in Menlo Park, California, is an early-stage venture capital firm that focuses on investments in the fintech, e-commerce, and healthcare sectors. The firm is renowned for backing innovative startups that challenge the status quo, including notable companies like MoneyLion, a digital bank aimed at the middle class, and PeerStreet, a tech-enabled real estate investment platform. Montage Ventures typically invests in the gap between Angel and Series A rounds, with an average investment size around $2M. They are involved in 7-12 deals per year, preferring to co-invest alongside other venture firms rather than leading rounds. The fund is particularly active in the United States, with significant investments in both the East and West Coasts. The firm’s strategy emphasizes supporting technical founders with deep industry knowledge and scalable solutions. Montage Ventures looks for startups with clear market demand and strong potential for growth. They prefer warm introductions and value detailed pitch decks that outline a clear business model and growth strategy. Startups looking to connect with Montage Ventures should demonstrate a robust product-market fit and innovative solutions within fintech, e-commerce, or healthcare. Their proactive and collaborative approach makes them a preferred partner for early-stage companies aiming for transformative impact.

Moonshots Capital is a seed-stage venture capital firm founded in 2017, with offices in Los Angeles and Austin. The firm focuses on investing in companies led by extraordinary leaders, particularly those who are military veterans or serial entrepreneurs. The co-founders, Kelly Perdew and Craig Cummings, leverage their extensive military and entrepreneurial experience to provide more than just capital to their portfolio companies, offering strategic guidance, operational support, and a vast network of contacts. Notable investments by Moonshots Capital include Slack, Robinhood, ID.me, and Bitium. The firm has a diverse portfolio that spans various sectors such as fintech, cybersecurity, consumer internet, and web3 technologies. Moonshots Capital takes an active role in the companies they invest in, often taking board seats or formal advisory roles to ensure they can provide maximum support and value. The firm's investment strategy prioritizes companies with strong leadership, a proven track record, and the potential for high growth. Moonshots Capital typically invests in companies that have a product with client traction, monthly recurring revenue of at least $100,000, and have raised at least $500,000 in previous funding rounds. They are particularly interested in companies at the seed or Series A stage that have a clear path to the next round of financing.

Moore Venture Partners (MVP) is a San Diego-area venture capital firm founded in 2010 and headquartered in Encinitas, California. The firm backs early, growth, and expansion-stage companies in technology and life sciences, with a particular emphasis on audacious founders building category-defining companies that can positively impact millions of lives. Core sectors include biotechnology, healthcare, and SaaS. Founder and Managing Partner Terry W. Moore brings more than 20 years of experience investing in, founding, leading, and advising technology, clean-tech, and life-sciences companies, and leads a lean team of two investment professionals consistent with the firm's measured investment pace of roughly one new investment per year. MVP has raised multiple fund vintages and is currently deploying its fourth fund, MVP IV, continuing to back life science and technology companies at all stages of growth. Individual check sizes can run up to USD 15 million, though formal fund size and AUM figures are not publicly disclosed. Across 29 disclosed portfolio companies the firm has produced one unicorn and two notable NASDAQ IPOs: Avidity Biosciences (NASDAQ IPO, June 2020, $636 million market cap at IPO), which advances antibody-siRNA complexes combining the modalities of ADCs and nucleic-acid therapeutics; and Savara Pharmaceuticals, which develops inhaled antibiotics for MRSA infection in cystic fibrosis. Portfolio sectors skew toward enterprise applications and life sciences. The most recent disclosed investment was a Series B in UCAP Power in February 2025. Moore Venture Partners takes a patient, high-conviction approach, committing deep operational and strategic support to each portfolio company rather than building a high-velocity fund. The firm's willingness to write checks from seed through late-stage Series C+ gives it the flexibility to follow founders through multiple rounds.

Morado Ventures is a venture capital firm focused on seed-stage investments, partnering with passionate entrepreneurs who tackle complex technological problems using both software and hardware solutions. Their current focus areas include Artificial Intelligence, Data Infrastructure, Industrial Internet, Robotics & Autonomy, Computer Vision, and Health. Founded by Ash Patel and Mike Marquez, Morado Ventures brings extensive experience in leading and investing in technology companies. Ash Patel, a former senior executive at Yahoo!, and Mike Marquez, with a background in corporate development at CBS Interactive and Yahoo!, co-founded the firm to leverage their expertise in identifying and nurturing promising startups. Morado Ventures' investment philosophy emphasizes supporting early-stage, data-fueled companies capable of solving significant challenges in industries ripe for disruption. They actively collaborate with founders to develop and execute successful strategies, providing access to a network of seasoned professionals and resources. Their portfolio includes a diverse range of companies such as Lucid Lane, Tensorfield Agriculture, and Cargomatic, reflecting their commitment to fostering innovation across various sectors.

Morgenthaler Ventures is one of the oldest venture capital and private equity platforms in the United States, founded in 1968 and headquartered in Portola Valley, California, with offices historically in Cleveland, Boulder, South San Francisco, Menlo Park, Massachusetts, and Hawaii. For more than 45 years the firm invested across information technology, life sciences, medical devices, healthcare services, pharmaceuticals, biotechnology, consumer and enterprise software, and mobile computing. Morgenthaler leads rounds. Its Information Technology, Life Sciences, and Private Equity teams together built more than 300 companies and made approximately 526 disclosed investments, producing 101 portfolio exits. Notable IT portfolio companies include Apple (early-stage), Evernote (unicorn), Lending Club (IPO), Siri (acquired by Apple), MuleSoft (acquired by Salesforce), Doximity (IPO, with Morgenthaler's stake valued at approximately $905 million), Practice Fusion, Check, Socrata, NuoDB, Jaspersoft, Voltage Security, and Wize Commerce. Fund IX closed in 2008 at $400 million as a combined IT and life-sciences vehicle. In 2013, IT partners Gary Little, Rebecca Lynn, and Gary Morgenthaler spun out the IT practice into Canvas Venture Fund, which closed at $175 million; the private-equity arm subsequently rebranded as MPE Partners in Cleveland. Morgenthaler Ventures still manages its legacy funds and portfolio under the original banner but no longer raises net-new institutional venture funds. The firm's most recent portfolio exit was FiveStar in November 2024. Across more than five decades the partnership earned a reputation as a generalist investor with the rare ability to back companies from inception through IPO in both technology and life sciences — a duality that few firms have sustained at Morgenthaler's scale and longevity.

Morningside Ventures is the venture capital investing arm of the Morningside Group, a long-standing private-capital platform founded in 1986 by Hong Kong-American brothers Gerald L. Chan, who serves as Chairman of Morningside Ventures, and Ronnie C. Chan, Chairman of Hang Lung Group. Headquartered in Newton, Massachusetts with additional operations in Hong Kong, the firm deploys patient capital across North America, Asia, and Europe with a long-term orientation and an explicit commitment to ethical practice. Life sciences is the dominant concentration, with the team recognized as a pioneer in oncolytic viral therapy, mitochondrial medicine, and innate-immunity modalities spanning toll-like receptors, the STING pathway, the complement cascade, and immune proteasomes. Portfolio companies have received seven FDA Breakthrough Therapy designations and twelve Fast Track designations — a track record few venture firms in any segment can match. The platform has made roughly 431 disclosed investments in aggregate. Average check sizes by stage are approximately $4.5 million at seed (17 deals), $23.9 million at Series A (42 deals), and $49.2 million at Series B (36 deals). Morningside leads rounds. Recent deals include leading a $105 million round in Cognito Therapeutics in March 2026, a $12 million Series B Plus in Accropeutics in March 2025, an $8.5 million pre-Series A in Ampa in October 2025, and an investment in digital health company Xealth in March 2025. The 2025 calendar saw 10 investments in total. Beyond capital, Morningside's philanthropic commitments to the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design reflect the firm's conviction that deep institutional relationships with leading research universities are essential to discovering and backing the next generation of breakthrough science.

Morningstar Ventures is a Dubai-based venture capital firm founded in 2020 by Danilo Carlucci and Arutyun Nazaryan. The firm focuses on investing in blockchain, digital assets, Web3, and decentralized finance (DeFi). With a portfolio spanning 199 investments, Morningstar has backed notable companies such as Unstoppable Domains and Axelar, both of which have achieved unicorn status. The firm typically participates in early-stage funding, ranging from Seed to Series A rounds, with investments averaging between $1 million to $5 million. Morningstar Ventures stands out for its deep involvement in the growth of its portfolio companies, providing not only capital but also strategic support and access to its vast network in the crypto and blockchain industries. In addition to its investment activities, Morningstar operates MSV GG, an initiative that supports Web3 startups by providing them with industry expertise and marketing resources. This holistic approach allows Morningstar to align closely with the companies it invests in, helping them scale rapidly in the competitive blockchain space. With its headquarters in Dubai, the firm has expanded its influence across various regions, focusing on fostering the next generation of decentralized technologies and contributing to the global adoption of blockchain​.

Morpheus Ventures, founded in 2016 and based in Los Angeles, focuses on early-stage investments in cutting-edge technologies such as data analytics, machine learning, robotics, and SaaS. Their portfolio includes innovative companies like Rigetti Computing, Vicarious, and Starship Technologies. The firm has made significant exits including Rigetti Computing and Vicarious (acquired by Alphabet). Other notable investments include HouseCanary, a real estate data analytics company, SafetyCulture, a leading safety and quality inspection software, and Sidecar Health, a health insurance platform. The leadership team at Morpheus Ventures includes experienced investors like Damien Petty, who has a background in artificial intelligence, robotics, and quantum computing, and has led investments in companies like DeepMind (acquired by Google) and Skype (acquired by Microsoft). The team focuses on identifying and nurturing companies with the potential to disrupt their respective industries and drive significant advancements in technology.

MTN Group is a leading telecommunications company based in Johannesburg, South Africa. The company has a strong presence across Africa and the Middle East, serving over 289 million subscribers. MTN Group's investment arm has made notable investments in sectors such as telecom infrastructure, renewable energy technology, and horizontal e-commerce. Key investments include companies like Fenix International, a renewable energy company acquired by ENGIE, and Jumia, a leading e-commerce platform in Africa. Another significant investment is in IHS Towers, one of the largest independent owners, operators, and developers of shared telecommunications infrastructure. MTN Group has committed substantial funds towards infrastructure projects to enhance its service delivery. For instance, it pledged $215 million for infrastructure investment in Benin over three years, focusing on building a state-of-the-art office for MTN Benin and expanding digital solutions across the region. Financially, MTN Group has reported strong performance with a 23.4% return on equity and a 10% increase in dividends to 330 cents per share. The group's strategic focus includes expanding its fintech ecosystem, investing in network infrastructure, and promoting digital inclusion across its markets.

Moving Capital, now known as Karman Ventures, is a venture capital firm founded by Uber alumni to support startups with innovative solutions. The firm has made notable investments across various sectors, including aerospace, artificial intelligence, retail technology, and green technology. Noteworthy investments by Karman Ventures include Whisper Aero, a company focusing on aerospace and green technology; Luca, which specializes in AI-driven retail technology; and Regent, which develops electric vehicles for marine transportation. Other significant investments are in companies like Gigs, focusing on mobile applications, and Kasa Living, a hospitality tech company. Karman Ventures is based in Austin, Texas, and has a strong network of co-investors, including prominent firms like Y Combinator, Menlo Ventures, and LaunchTN. Their investment strategy typically involves supporting companies from seed to growth stages, emphasizing scalable and transformative technologies.

Moxxie Ventures is a venture capital firm founded in 2019 by Katie Jacobs Stanton, a former Twitter executive and co-founder of the #ANGELS investment collective. The firm is based in Mountain View, California, with a secondary office in Boulder, Colorado. Moxxie Ventures focuses on early-stage investments, particularly in consumer, enterprise, fintech, healthtech, and climate sectors. Moxxie Ventures recently closed its second fund at $85 million, a significant increase from its inaugural $25 million fund. The firm typically writes checks ranging from $250,000 to $500,000 and aims to make 10 to 12 investments per year, reserving half of the fund for follow-on investments. Notable investors backing Moxxie Ventures include Bain Capital Ventures, Bloomberg Beta, Foundry Group, and individual investors such as Marc Andreessen, Susan Wojcicki, and Jerry Yang. The firm prides itself on bringing a combination of capital, operating experience, and a strong network to its portfolio companies. Stanton and her team leverage their extensive backgrounds in product, engineering, marketing, and business development to support founders in scaling their businesses. Moxxie Ventures is committed to partnering with founders who are passionate about making life and work better through innovative solutions. Some of their notable investments include companies like Elpha, Carta, and Clubhouse. The firm continues to build on its mission to support founders with not just funding but also strategic guidance and connections to a broad network of industry experts and leaders.

MPM Capital, founded in 1997, is a leading venture capital firm based in Boston and San Francisco, specializing in biotechnology and life sciences investments. The firm has a robust portfolio, having invested in over 150 companies, including notable names like 23andMe, ReNAgade Therapeutics, and Argenx. MPM Capital's focus is on transforming innovative scientific discoveries into breakthrough medicines, particularly in oncology and other high-need therapeutic areas​. MPM Capital recently raised $850 million for its second Oncology Impact Fund, marking it as one of the largest biotech impact investment funds globally. This fund emphasizes investments in companies developing novel cancer therapies, reflecting MPM's deep commitment to addressing significant medical challenges. The firm's team includes seasoned professionals with extensive experience in research, drug development, and corporate strategy. Key team members like Dr. Luke Evnin and Dr. Ansbert Gadicke bring invaluable expertise to the firm, guiding its strategic investments and supporting portfolio companies through various growth stages​ .

Mubadala Capital’s Ventures platform stands out as a leading global investor, blending the strengths of Mubadala Investment Company with the agility of a venture capital firm. Focused on technology and healthcare sectors, Mubadala has made over 75 investments, including notable startups like Chroma Medicine, Recursion Pharmaceuticals, and Exscientia. Their strategy revolves around partnering with visionary founders to build enduring companies, leveraging Mubadala’s extensive resources and global scale. Geographically, Mubadala Ventures operates with a significant presence in technology hubs such as San Francisco, London, and Abu Dhabi, ensuring deep integration into the global innovation ecosystem. They emphasize Series A+ investments in the U.S. and Series B+ in Europe, providing substantial capital and strategic support to their portfolio companies. Mubadala's investment strategy is marked by a focus on capital preservation and downside protection, ensuring sustainable growth and returns. The fund typically invests in founder-led companies, with average check sizes tailored to the needs of each growth stage. They are known for their disciplined approach to evaluating opportunities, benefiting from Mubadala's broad network and sovereign backing. The team at Mubadala Ventures includes industry veterans like Ibrahim Ajami, Head of Ventures, and Alaa Halawa, Co-Head of US Ventures. Their expertise spans various sectors and geographies, further strengthening Mubadala’s investment acumen. Startups looking to engage with Mubadala are advised to highlight their alignment with Mubadala’s strategic focus and demonstrate robust business models that can benefit from Mubadala’s vast resources and network.

Mucker Capital, founded in 2012 and headquartered in Los Angeles, is a venture capital firm that invests in seed and early-stage startups across the United States, Canada, and beyond. With additional offices in Austin and Toronto, Mucker Capital focuses on internet-enabled software and services, aiming to support startups outside the traditional Silicon Valley ecosystem. The firm believes that great companies can be built anywhere and provides tactical help, networking opportunities, and a bridge to Silicon Valley resources. Notable portfolio companies include Honey, acquired by PayPal; Surf Air, which went public on NASDAQ; and ServiceTitan, a business management software for home service providers. Mucker Capital has also backed companies like The Black Tux, ServiceTitan, and BloomNation. MuckerLab, their pre-seed accelerator, is highly regarded and ranked second in the U.S. by the Seed Accelerator Rankings Project based on valuations, exits, fundraising, survival, and founder satisfaction. Mucker Capital's approach includes rolling up their sleeves to work alongside entrepreneurs on product development, marketing, sales, recruiting, and other critical areas to help startups succeed. The firm has launched multiple funds, including Mucker III, a $45 million seed-stage fund, and continues to support the growth and scaling of innovative startups.

Muse Capital is an early-stage venture capital fund based in Los Angeles, California, focused on investing in consumer-facing startups. Founded in 2016, the firm aims to bridge the gap between Silicon Valley, the entertainment industry, and the corporate sector, providing strategic capital and partnership-based business development. Muse Capital has a diverse portfolio that includes companies like CoFertility, Beekeeper's Naturals, Cloud Paper, and Firefly, all of which are pushing boundaries in telehealth, education, motherhood, gaming, and underserved markets. The firm is led by Assia Grazioli-Venier and Rachel Springate, who leverage their extensive networks in the entertainment and corporate worlds to support their portfolio companies. Muse Capital typically invests in seed-stage rounds, providing both financial backing and strategic guidance to help startups grow and succeed. Muse Capital is particularly known for its active involvement in the companies it invests in, offering tactical insights and connections to key industry players. This hands-on approach has made Muse a valuable partner for entrepreneurs looking to disrupt and innovate within the consumer sector. For startups looking to engage with Muse Capital, demonstrating a clear vision for consumer impact and leveraging the firm’s entertainment and corporate connections can be crucial.

Musa Ventures is a cutting-edge platform dedicated to improving the funding readiness of startups and small to medium businesses (SMBs). They leverage advanced analytics, artificial intelligence, and machine learning to deliver comprehensive venture health assessments. This holistic approach goes beyond financial metrics, providing founders with detailed insights into their ventures' strengths and areas needing improvement. The platform offers intelligent venture health dashboards that give real-time feedback and actionable recommendations. These dashboards are designed to help founders understand strategic gaps and enhance their appeal to potential funders. By offering objective feedback and insights from experienced advisors, Musa Ventures aims to make the fundraising process more transparent and accessible. Musa Ventures also employs proprietary assessment tools developed from over 30 years of global experience and research into ventures and SMBs. These tools analyze data from more than 20,000 ventures and involve input from over 600 funding firms, ensuring a robust and reliable evaluation process. In addition to assessments, Musa Ventures uses algorithmic matching to connect funding-ready ventures with suitable funders or partners. This approach helps streamline the funding process, making it easier for businesses to secure the right type of funding from the right sources. Musa Ventures thus plays a pivotal role in fostering a symbiotic relationship between startups and financial backers, ultimately contributing to healthier and more successful business ventures.

MVM Partners, founded in 1997, is a global venture capital firm focused on high-growth healthcare investments. With offices in Boston and London, MVM invests broadly across sectors including medical technology, pharmaceuticals, diagnostics, digital health, and other healthcare-related fields. Their portfolio includes notable companies such as SkyCell, which developed patented temperature-control technology for safely transporting vaccines and biotech drugs, and Ossio, which created OSSIOfiber Intelligent Bone Regeneration Technology—a novel orthopedic fixation material that integrates into native bone and avoids the need for permanent metal implants. MVM also invested in MDxHealth, a company specializing in molecular diagnostics for urologic cancers, which enhances personalized cancer diagnosis and treatment. MVM's investment strategy emphasizes significant minority stakes in innovative companies, providing both financial support and strategic guidance to help these companies grow and scale. Their approach involves close collaboration with management teams to drive business development and market expansion. MVM's recent investments include companies like eXmoor Pharma, which focuses on cell and gene therapy services, and Nalu Medical, which develops minimally invasive solutions for chronic pain management. These investments reflect MVM's commitment to supporting advancements in medical technology and improving patient outcomes globally.

My Climate Journey Collective (MCJ Collective) is a venture capital firm dedicated to investing in innovative climate solutions. Founded to drive significant impact in combating climate change, MCJ Collective supports early-stage startups across a range of sectors including renewable energy, mobility, food systems, and sustainable infrastructure. MCJ Collective's portfolio includes notable companies such as BlocPower, which focuses on clean energy and smart city solutions, and Arcadia, a technology company democratizing access to clean energy. They have also invested in Enode, a developer of APIs for information services, and Hoxton Farms, a biotechnology company working on sustainable food solutions. The firm is known for its broad investment strategy, backing startups that aim to mitigate climate change and improve environmental sustainability. They have a strong focus on sectors like renewable energy, electrification, carbon management, and the built environment. MCJ Collective emphasizes the importance of technological innovation in addressing climate challenges, supporting companies that leverage AI, data centers, and other advanced technologies. The team at MCJ Collective includes experienced professionals with a deep understanding of climate issues and investment strategies, ensuring that they provide not only capital but also strategic guidance to their portfolio companies. For more detailed information, you can explore their portfolio and insights on their official.

Mystic Ventures, founded in 2021 and based in Los Angeles, is a venture capital firm focused on the rapidly growing psychedelic medicine and mental health sector. The fund is committed to advancing research and developing innovative treatments using psychedelics to address conditions like depression, anxiety, PTSD, and other mental health issues. Mystic Ventures typically invests in pre-seed and seed-stage companies that are pioneering these therapies. Led by Jeremy Gardner and Brock Pierce, the firm takes a biotech-oriented approach, partnering with scientific research teams and pharmaceutical experts to bring cost-effective, holistic psychedelic solutions to the mainstream. With a rolling fund structure on AngelList, Mystic Ventures is uniquely positioned to offer flexible capital to startups, supporting their long-term growth in the burgeoning field of psychedelic therapeutics. The fund has backed companies like Psylo and Heading Health, among others. By investing in breakthrough treatments that go beyond traditional pharmaceutical approaches, Mystic Ventures aims to reshape how mental health treatments are developed and accessed, while offering investors exposure to this transformative market.

Nama Ventures is a seed-stage venture capital fund based in Riyadh, Saudi Arabia, focused on fueling innovation across the MENA region, particularly in Saudi Arabia. Founded by Mohammed Alzubi, the fund is committed to nurturing early-stage technology startups with a strong emphasis on team-based ventures over solo founders. Their portfolio includes notable investments like PIESHIP in logistics, palm.hr in business productivity software, and Brev.dev, an AI and ML platform recently acquired by NVIDIA. Nama Ventures emphasizes supporting startups from pre-seed to seed stages, often leading funding rounds and providing strategic guidance to help ventures grow and realize their potential. They have invested in 47 companies, achieving several successful exits, including the acquisition of Brev.dev by NVIDIA. The fund recently launched a $27 million fund to further invest in MENA startups, with some allocations for Silicon Valley-based ventures through strategic syndication partners. Nama Ventures' investment strategy is centered around fostering technology innovation and supporting startups with complementary skill sets in their founding teams. For startups looking to approach Nama Ventures, it's crucial to demonstrate a robust team dynamic, innovative technology, and the potential for significant impact and growth within the targeted markets. The leadership team, including Mohammed Alzubi, brings extensive experience from Silicon Valley, offering a wealth of knowledge and a strong network to support portfolio companies in achieving their goals and scaling their businesses effectively.

Navigare Ventures, founded in 2021 and based in Stockholm, is an early-stage venture capital firm specializing in science-driven companies. As a subsidiary of Wallenberg Investments AB, Navigare Ventures focuses on deep tech sectors, including advanced computing, quantum technologies, synthetic biology, bio innovation, and data-driven life sciences. The firm is committed to investing in transformative technologies that have a strong industrial and societal impact. Navigare Ventures typically invests in Seed and Series A rounds, partnering closely with founders to support the growth and development of their companies. The firm has a robust portfolio that includes companies like Elypta, a startup developing metabolism-based liquid biopsy technology for cancer detection, and EnginZyme, which focuses on sustainable biomanufacturing. Their investment strategy is characterized by long-term partnerships, leveraging an extensive network of scientific and industrial expertise to help startups scale and succeed in their respective fields​.

Necessary Ventures is a San Francisco-based venture capital firm focused on investing in early-stage companies that address significant societal needs. The firm is led by Neil Devani, who brings extensive experience in both venture capital and entrepreneurship. Necessary Ventures primarily invests in companies across a range of sectors including health tech, financial services, biotechnology, and sustainability. Notable investments in their portfolio include Recursion Pharmaceuticals, a company revolutionizing drug discovery through advanced computational methods; Rubi Laboratories, which converts CO2 into sustainable textiles; and Andela, a tech talent training and employment platform. Additionally, they have backed Vicarious Surgical, which develops minimally invasive robotic surgery technology, and Wayve, an AI-driven autonomous vehicle company. The firm is known for its hands-on approach, providing not just capital but also strategic guidance and support to help their portfolio companies scale and succeed. They emphasize a collaborative and empathetic partnership with founders, aiming to create long-term value and impact. Necessary Ventures has a strong presence in both the U.S. and international markets, with investments in various high-growth regions. They have co-invested with leading venture funds such as Y Combinator, Collaborative Fund, and Talis Capital, highlighting their integration into a robust network of investors.

Neo is a venture capital firm based in San Francisco, founded by Ali Partovi, with a strong emphasis on supporting the next generation of tech leaders. Launched in 2012, Neo invests primarily in early-stage startups, often serving as the first institutional investor for many high-growth companies. Neo focuses on industries like AI, consumer internet, and education, investing in startups that have the potential to drive significant innovation. Neo’s investment strategy is centered on a hands-on approach, offering both financial backing and access to a powerful network of industry leaders. With check sizes ranging from $100K to $5 million, Neo supports startups from seed through Series A stages. They also place a high value on mentorship, connecting founders with an elite community of experienced entrepreneurs, engineers, and executives who offer guidance throughout the startup journey. The firm's portfolio includes some of the most promising startups in the tech space, such as Gusto, Pachama, and Notion. Neo prides itself on fostering diversity and inclusion, believing that the best tech companies are built by teams from a variety of backgrounds. Led by Ali Partovi and supported by a team of seasoned investors and operators, Neo is committed to making a long-term impact in the startup ecosystem by focusing on companies that combine technological innovation with meaningful social impact.

Neotribe Ventures, founded in 2017 and based in Menlo Park, California, is a venture capital firm that focuses on investing in breakthrough technologies across various sectors including applied artificial intelligence, biotech, enterprise infrastructure, and the internet of things. The firm targets early to growth-stage companies that are shaping the future through innovative solutions. Neotribe Ventures has made 98 investments with notable companies in its portfolio such as Energy Vault, Heliogen, and CipherTrace. The firm has achieved 17 exits, including significant companies like Robinhood, which went public in July 2021. Other successful exits include Pluribus Networks and ClearMotion. The firm is led by co-founders Swaroop Kolluri and Steven Bragonier, along with partners like Nitin Chopra and Neeraj Hablani. Neotribe Ventures manages nearly $450 million in assets across three funds, including the recent Ignite Fund, which focuses on growth-stage investments. Neotribe Ventures' strategy involves providing not just capital but also extensive support and resources to help their portfolio companies succeed. The firm's emphasis on deep technology and innovative solutions makes it a significant player in the venture capital landscape​.

Neulogy Ventures, established in 2014 and based in Bratislava, Slovakia, is a Luxembourg-regulated venture capital fund. The firm focuses on early-stage tech companies, particularly those operating in Slovakia and the Central and Eastern Europe (CEE) region. Neulogy Ventures manages €65 million in assets, with a diverse portfolio spread across 10 countries. The fund targets investments in sectors like media, cleantech, data analytics, productivity applications, medtech, infrastructure, fintech, security, 3D, e-commerce, and new energy. Neulogy Ventures aims to support mission-driven entrepreneurs with bold ideas that push technological frontiers, particularly those addressing climate change and healthcare challenges. Neulogy Ventures emphasizes a hands-on approach, offering strategic guidance, business development support, and fundraising assistance to its portfolio companies. The firm values long-term partnerships, prioritizing shared values and a collaborative approach over quick exits. Notable companies in Neulogy's portfolio include GA Drilling, GreenWay, and GroupSolver. The team, led by managing partners Christian Mandl and Jaroslav Luptak, brings extensive experience in entrepreneurship, fundraising, and business development, ensuring robust support for their investees.

NeuroVentures Capital is a venture capital firm founded in 2000 and based in Charlottesville, Virginia, that claims to be the largest fund in the United States focused exclusively on the neuroscience space. The firm invests in companies developing drugs, medical devices, therapeutics, and technologies to treat central nervous system disorders including stroke, chronic pain, epilepsy, Parkinson's disease, and depression. NeuroVentures manages approximately $15 million and writes tickets ranging from $200,000 to $2 million, backing both development-stage and later-stage companies at seed, Series A, and Series B. The firm is led by Managing Director Mark Cochran, a PhD molecular biologist from Queen's University with postdoctoral training at the NIH, who previously served as VP of Business Development at Bayer Pharmaceuticals, founded MicroGeneSys Inc., and ran the San Francisco office of Toronto-based MDS Capital Corp. He is joined by Director Daniel O'Connell, who has operated multiple medical and healthcare startups. The firm's scientific advisory board includes Floyd Bloom of Scripps Research, Zach Hall (former director of NIH's National Institute of Neurological Disorders and Stroke), William Mobley of Stanford Neurology, and Donald Price of Johns Hopkins. NeuroVentures has made approximately 27 investments with four exits: one IPO — Acumen Pharmaceuticals, listed in July 2021 — and three acquisitions including Concentric Medical and Saegis Pharma. Other notable portfolio names include BrainCells Inc., which raised a $17.7 million Series A in 2005, EnVivo Pharmaceuticals, and Kadmus Pharmaceuticals. NeuroVentures Capital's singular focus on CNS diseases gives it scientific credibility and a curated network of neurologists, pharmacologists, and device engineers that few generalist life-science funds can replicate.

New Age Capital, founded in 2016 by Ivan Alo and LaDante McMillon, is a New York-based venture capital firm focusing on seed-stage investments in tech and tech-enabled startups led by Black and Latino entrepreneurs. The firm aims to bridge the funding gap for underrepresented founders by providing not only capital but also strategic guidance and access to a robust network of investors and partners. The firm typically invests between $850,000 and $1 million per company, targeting an ownership stake of 10-15%. New Age Capital prefers to lead funding rounds and maintains a hands-on approach, fostering long-term relationships with founders well in advance of their capital needs. This strategy allows the firm to provide tangible value and support through various growth stages. New Age Capital's portfolio includes a diverse array of companies such as Myavana, a personalized hair care recommendation platform; PredictionStrike, a sports stock market; and Navigate Maternity, which uses data to support prenatal and postpartum care. The firm's emphasis on authenticity, empathy, and transparency has positioned it as a trusted partner for founders from historically underfunded communities. By focusing on capital-efficient, high-potential startups in large and fragmented markets, New Age Capital aims to generate outsized returns while driving significant impact in the entrepreneurial ecosystem.

New Enterprise Associates (NEA) is a global venture capital firm with a storied history of supporting innovative businesses. Founded in 1977, NEA manages over $25 billion in assets and invests across all stages of a company's lifecycle, from seed stage to IPO. The firm has a diverse portfolio that spans technology and healthcare sectors. NEA's notable investments include companies like 23andMe, Coursera, Robinhood, and Uber, highlighting their focus on transformational businesses. They have facilitated over 270 IPOs and more than 450 mergers and acquisitions, underscoring their impact on the market. The firm operates from key locations in Menlo Park, California, and New York City, but their investment reach is global, covering North America, Europe, Asia, and beyond. NEA's strategy involves not just funding but also actively mentoring and supporting their portfolio companies through various stages of growth. Recently, NEA closed on two new funds totaling $6.2 billion, the largest in the firm's history, aimed at early-stage and growth-stage investments in sectors like enterprise tech, fintech, digital health, and life sciences. This reflects NEA’s commitment to driving innovation and supporting founders with the capital and expertise needed to build successful companies.

NLV Partners, founded in 2005, is a leading venture capital firm focused on revolutionizing healthcare. With notable investments in companies like CRISPR Therapeutics, Akili Interactive Labs, and iRhythm Technologies, NLV Partners targets biopharmaceuticals, diagnostics, medical devices, and healthcare IT. Their portfolio boasts 30 billion-dollar companies and numerous successful exits, reflecting their impact in the industry. Geographically, NLV Partners concentrates on the United States, partnering with businesses from startup stages to public offerings. Their investment strategy involves backing visionary teams and disruptive healthcare technologies. They aim to develop commercially attractive and clinically important healthcare solutions, leveraging decades of experience and deep domain expertise to navigate the complex healthcare landscape. NLV Partners typically leads investment rounds, providing not only capital but also strategic guidance. They prefer to be approached through well-prepared pitches that clearly demonstrate the potential for clinical and commercial success. The fund's average check size varies, tailored to the needs of each investment. The team includes co-founders Ron Hunt and Vijay Lathi, based in New York and Menlo Park respectively. Both bring extensive experience in healthcare investments and have been instrumental in shaping the firm's strategic direction. For startups seeking a partner with profound industry knowledge and a track record of success, NLV Partners stands out as a pivotal ally in the healthcare sector.

VisVires New Protein, recently rebranded as Clay Capital, is a Singapore-based venture capital firm dedicated to transformative investments in the agrifood tech sector. Founded in 2014, Clay Capital focuses on supporting innovative startups that address fundamental challenges in the food system, particularly in the areas of sustainable packaging, fermentation, agricultural biologicals, crop disease resistance, soil health, and regenerative agriculture. Notable investments include French biostimulant producer Toopi, Israeli bioherbicide startup WeedOUT, and French kitchen robot manufacturer Cook-e. These investments reflect Clay Capital's commitment to leveraging technology to improve sustainability and efficiency in the food and agriculture sectors. Clay Capital's strategy involves investing in early-stage to growth-stage startups, typically with initial checks ranging from $3 million to $8 million, and reserving additional capital for follow-on investments. The firm serves as a bridge between the Asian and European markets, providing startups with support to access and expand in these regions. The rebranding from VisVires New Protein to Clay Capital signifies a renewed focus on building a healthy and sustainable food system, symbolizing fertile ground for growth and innovation. With a newly raised $145 million fund, Clay Capital is well-positioned to continue driving impactful changes in the agrifood tech landscape

New Science Ventures (NSV) is a premier venture capital firm established in 2004, with offices in New York and London. The firm specializes in investing in companies that leverage groundbreaking scientific innovations in the life sciences and information technology sectors. NSV has a keen focus on businesses with strong IP protection and those addressing significant unmet market needs. Notable investments include Ventyx Biosciences, Phase Four, Achronix Semiconductor, and Paragraf. NSV is particularly interested in companies that can transform their industries with innovative scientific approaches. Their strategy is to invest in both early and mid-stage companies, supporting them through crucial growth phases to maximize their potential and value. NSV is not afraid to take contrarian views and often seeks opportunities outside traditional tech hubs, emphasizing the importance of science-based innovation. The firm typically leads funding rounds and provides substantial follow-on support, ensuring that their portfolio companies have the resources needed to succeed. Key team members include co-founder Tom Lavin, who brings over 30 years of experience in finance and investment banking, and Raju Mohan, a seasoned biotech entrepreneur and senior advisor with extensive expertise in drug discovery and development. Startups looking to engage with NSV should emphasize their scientific uniqueness and potential for significant market impact. NSV values strong management teams and clear, defensible IP strategies, making these essential points of focus when approaching the firm.

NewSpring Capital, founded in 1999 and headquartered in Radnor, Pennsylvania, is a private equity firm focusing on growth equity, mezzanine capital, healthcare, and buyouts. The firm manages approximately $3.5 billion in assets and has invested in over 250 companies across various sectors. Notable investments in NewSpring's portfolio include Vacasa, a leading vacation rental management company; Innovid, a video marketing platform; and Nutrisystem, a weight management company. These investments reflect NewSpring's strategy of supporting high-growth companies in business services, healthcare, information technology, and consumer products. NewSpring Capital operates through multiple strategies, including NewSpring Growth, which targets high-growth technology companies; NewSpring Healthcare, focusing on innovative healthcare services and technology; and NewSpring Mezzanine, providing capital for acquisitions and recapitalizations. The firm's comprehensive approach allows them to support companies at different stages of their lifecycle, from early growth to expansion.

New Stack Ventures is an early-stage venture capital firm focused on investing in founders who are often overlooked by traditional venture capital firms. Founded by Nick Moran, New Stack Ventures targets startups in under-capitalized markets and geographies, with a particular focus on IoT, deep tech, smart hardware, and various platform-based business models. The firm recently closed its second fund, New Stack Ventures Fund II, at $42.6 million, significantly larger than its first $6 million fund. This new fund allows New Stack to support an additional 35 companies at the pre-seed and seed stages. The firm prides itself on being one of the largest single-partner funds raised outside of the typical Silicon Valley ecosystem, emphasizing its commitment to backing "outsider" founders. New Stack Ventures has built a strong reputation for its proactive and founder-friendly approach. The firm was highlighted by TechCrunch as one of the most active and engaged investors in the industry. Its portfolio includes notable companies like Draftbit, Curv, and Flamingo, reflecting its diverse investment strategy. The team at New Stack Ventures is comprised of experienced professionals, including Nate Pierotti, Luke Skertich, and Ariella Frank, who bring extensive backgrounds in startups, product management, and venture capital. Their collaborative and inclusive investment process ensures they identify and support high-potential startups effectively.

New York Angels, founded in 2004, is one of the most active and well-established angel investor groups based in New York City. Specializing in early-stage investments, the group has made over 386 investments, with notable successes including Greenhouse Software, Payoneer, and Billtrust. Their portfolio spans various sectors such as Artificial Intelligence, Fintech, Healthcare, and SaaS. New York Angels typically invests in increments starting from $25,000 and expects its members to invest a minimum of $50,000 annually in its deals. Their average investment round size is around $2 million, and they are known for both leading and participating in follow-on rounds. The group has achieved 72 exits, indicating a strong track record of identifying and nurturing high-potential startups. The investment strategy of New York Angels emphasizes thorough due diligence and a collaborative approach, leveraging the diverse expertise of its members. They actively engage with their portfolio companies, providing not only capital but also valuable mentorship and networking opportunities. Key figures in the organization include founder David S. Rose, who has played a pivotal role in shaping the group's investment philosophy and operations. Startups looking to secure funding from New York Angels should be prepared to demonstrate strong business fundamentals and a clear growth trajectory

New York Venture Partners, founded in 2014, is a venture capital firm based in New York City. NYVP focuses on early-stage investments, particularly in seed rounds, and aims to support startups with both capital and strategic guidance. The firm has a diverse portfolio with investments across various industries, including enterprise software, cybersecurity, AI, fintech, and health tech. NYVP is known for its notable investments in companies like VHX, Food52, and CrowdTwist, which have achieved significant market success. The firm typically invests check sizes ranging from $300,000 to $700,000, allowing it to support startups through critical early development phases. NYVP's investment strategy emphasizes partnering with innovative entrepreneurs and providing them with resources beyond just financial support. This includes access to experienced advisors who can offer strategic guidance, as well as operational support to help with recruiting and fundraising efforts.

Newark Venture Partners is a seed-stage venture capital firm based in Newark, New Jersey, with a strong focus on B2B software companies. Founded in 2015, NVP aims to support innovative startups by providing seed funding and operational support to foster growth and success. The firm has raised approximately $90 million for its second fund, doubling the size of its first fund. NVP's investment strategy revolves around healthcare, fintech, and supply chain sectors, seeking startups that offer transformative solutions in these high-stakes industries. The firm’s portfolio includes notable companies like Podsights, Optimal Dynamics, and Handspring Health, highlighting their commitment to driving innovation in enterprise software. The team at NVP is led by Managing Partners Tom Wisniewski, Dan Borok, and Vaughn Crowe, who bring extensive experience in venture capital and entrepreneurship. The firm is known for its active involvement in the Newark community, including partnerships with organizations like the Boys and Girls Club of Newark and Braven, which support local talent and promote educational and employment opportunities.

Newfund Capital, founded in 2008, is an entrepreneurial venture capital firm with a strong presence in both Paris and Silicon Valley. With $300 million in assets under management, Newfund focuses on seed-stage startups driving global change. Notable investments include Aircall, Fairmoney, and In2Bones, showcasing their diverse and impactful portfolio. The firm invests primarily in technology, precision medicine, personalized treatment, and brain tech sectors. They emphasize early-stage investments, aiming to support startups from the seed stage through international expansion, particularly in France and North America. Newfund's strategy involves quick decision-making, often providing term sheets within three weeks. They seek entrepreneurs with a global mindset and provide significant value beyond capital, including scaling opportunities, networking, and strategic support. The average check size varies but is tailored to meet the needs of each startup, with Newfund often leading the investment rounds. The team includes key members like Henri Deshays and Patrick Malka, who bring extensive entrepreneurial and investment experience. The team is split between their Paris and Palo Alto offices, allowing them to maintain a strong presence in both Europe and the U.S. For startups looking to scale rapidly with a partner who understands the entrepreneurial journey, Newfund Capital offers a compelling blend of expertise, resources, and strategic guidance.

Newgen Venture Partners is a global angel and seed fund platform founded in 2012 and headquartered in Shanghai, China, with additional offices in Beijing, Hong Kong, and Palo Alto. The firm backs entrepreneurs working in life science and information technology with the most innovative ideas and disruptive technologies, explicitly targeting world-class management and technical teams pursuing disruptive opportunities across TMT, life science, and emerging technology. Newgen is led by Founder and Managing Partner Lu Zhang, who has built the firm into a portfolio of more than 100 companies with accumulated valuations exceeding RMB 50 billion (approximately $7 billion). Newgen leads rounds and is often the first institutional investor in its portfolio companies, writing early seed checks of $100,000 to $3 million. Notable portfolio companies include GrubMarket, a US online grocery and food supply-chain platform that received Newgen's first check at seed in January 2015 and most recently raised a $50 million Series H at a $4.5 billion pre-money valuation in February 2026; HotMaxx, a Chinese food and fast-moving-consumer-goods discount retailer; LePure, a Chinese biotech; and WePie. Portfolio exits include Kheiron Medical Technologies, an AI radiology company acquired by DeepHealth in October 2024, and Paperspace, a cloud GPU infrastructure company. In 2025 to 2026, Newgen led the undisclosed Series A of TuCodec alongside Angel Bay Ventures and MFund. Beyond direct investing, Newgen Capital operates as a limited-partner arm, backing emerging VC funds such as ZPARK Venture and GSR Ventures vehicles, positioning the firm as a platform that accelerates the broader early-stage ecosystem rather than purely deploying direct capital.

Newpath Partners is a Boston-based venture capital firm specializing in life sciences. Founded in 2018 by Dr. Thomas Cahill, Newpath focuses on building biotechnology companies from the ground up, partnering with leading academic scientists to translate groundbreaking scientific discoveries into transformative therapies. With a strong commitment to high-impact ventures, the firm is particularly known for its deep involvement in the early stages of company formation, often acting as a founding investor. Newpath Partners manages multiple funds, with its second fund, raised in 2021, amounting to $350 million. This fund continues Newpath’s mission to back companies with high scientific originality and ambitious goals, particularly in areas like regenerative medicine, genomics, and oncology. The firm typically invests in early-stage ventures, providing not only capital but also strategic guidance and access to a network of industry leaders. Dr. Cahill, who also founded the nonprofit Scientists to Stop COVID-19, leads a team that is highly experienced in both science and business, ensuring that the companies they back are well-positioned to make a significant impact in the life sciences arena. Newpath’s approach is characterized by a close collaboration with founders, aligning interests across scientists, investors, and management teams to drive innovation and success.